Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ13KI)

• Drug Name: Terconazole Drug Info
• Synonyms: Fungistat; Terazol; Terconazol; Terconazolum; Tercospor; Triaconazole; Zazole; R 42470; Terazol 3; Terazol 7; Terazol 73; Tetrazol 3; Tetrazol 7; Gyno-Terazol; R 42,470; R-42470; Terazol 3 (TN); Terazol 7 & 3; Terazol Cream & Suppositories; Terconazol [INN-Spanish]; Terconazolum [INN-Latin]; Terconazole (USAN/INN); Terconazole [USAN:INN:BAN]; Cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine

Indication

Disease Entry	ICD 11	Status	REF
Candidiasis	1F23	Approved	[1]

• Therapeutic Class: Antifungal Agents
• Cross-matching ID:
  PubChem CID: 441383
  ChEBI ID: CHEBI:82980
  CAS Number: CAS 67915-31-5
  TTD Drug ID: DMJ13KI
  ACDINA Drug ID: D01477

Molecule-Related Drug Atlas

Drug(s) Targeting Candida Cytochrome P450 51 (Candi ERG11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[5]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[5]
Posaconazole	DMUL5EW	Aspergillosis	1F20	Approved	[6]
Ketoconazole	DMPZI3Q	Blastomycosis	1F22	Approved	[7]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[5]
Oxiconazole	DME7KRM	Tinea corporis	1F28.Y	Approved	[8]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[5]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[9]
Tioconazole	DMNYPGS	Onychomycosis	EE12.1	Approved	[10]
Econazole	DMFSWGH	Cutaneous candidiasis	1F23.14	Approved	[11]

Drug(s) Affected By Tissue factor (F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[12]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[13]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[14]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[15]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[16]
Fructose	DM43AN2	Vomiting	MD90	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[19]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[20]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[21]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[22]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[23]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[23]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[24]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[25]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[26]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[27]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[3]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Gene/Protein Processing	[4]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021735.
• [2] Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
• [3] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [4] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
• [7] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
• [8] Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
• [9] Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
• [10] Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
• [11] Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
• [12] Inhibition of interleukin-1-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2. Oncotarget. 2016 Sep 20;7(38):61438-61457. doi: 10.18632/oncotarget.11367.
• [13] The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol. 2003 Jan;120(2):315-24. doi: 10.1046/j.1365-2141.2003.03971.x.
• [14] Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Arch Toxicol. 2019 Jan;93(1):121-136.
• [15] Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000 May 15;69(9):1830-6. doi: 10.1097/00007890-200005150-00017.
• [16] Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J Thromb Haemost. 2003 May;1(5):1089-95. doi: 10.1046/j.1538-7836.2003.00217.x.
• [17] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [18] Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999 Jul;13(7):1062-70. doi: 10.1038/sj.leu.2401448.
• [19] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [20] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [21] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [22] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [23] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [24] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [25] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [26] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [27] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.